<p>
    Donor Selection and Factors
</p>
<p>
    Deceased donors are assessed based on various clinical and histological factors. Patients undergoing liver transplantation for fulminant hepatic failure or re-transplantation should ideally receive grafts with one or no abnormal donor factors.&nbsp;
</p>
    <table class="table table-bordered">
        <tbody>
            <tr class="table-secondary">
                <td>
                    Donor Factors &nbsp;&nbsp;
                </td>
                <td>
                    Details
                </td>
            </tr>
            <tr>
                <td>
                    Age &nbsp;
                </td>
                <td>
                    <ol>
                        <li data-list-item-id="ea4ce2956314b282de9c3fdf5f6b685db">
                            &nbsp; &nbsp; &lt; 55 (Use).
                        </li>
                        <li data-list-item-id="e7b8c82247a88b95c102713562cb752ee">
                            &nbsp; &nbsp;55-60 (Use if only one other donor factor abnormal).
                        </li>
                        <li data-list-item-id="eae178b90f4451ebaf82b28359162b76e">
                            &nbsp; &nbsp;&gt; 60 (only Use if no other risk factors present).&nbsp;
                        </li>
                    </ol>
                </td>
            </tr>
            <tr>
                <td>
                    Macro steatosis &nbsp;&nbsp;
                </td>
                <td>
                    <ol>
                        <li data-list-item-id="ec95aab42d6f4acdef1148b99fde3d669">
                            &nbsp; &nbsp;Macro steatosis &lt; 30% (Use) &nbsp;
                        </li>
                        <li data-list-item-id="ef12225d620cf6f8df7949ed602e36b0f">
                            &nbsp; &nbsp;Macro steatosis 30-60% (Only Use if no other risk factor present) &nbsp;
                        </li>
                        <li data-list-item-id="e9a3f279133b04c34eed69e21424fba71">
                            &nbsp; &nbsp;Macro steatosis &nbsp;&gt; 60% (Never Use) &nbsp;
                        </li>
                    </ol>
                </td>
            </tr>
            <tr>
                <td>
                    HBV &nbsp;
                </td>
                <td>
                    <p>
                        &nbsp;1. Donors with HBsAg + with minimal fibrosis and no focal lesions are considered Use in recipients with HBsAg + ( will need HBV anti-viral). &nbsp;
                    </p>
                    <ul>
                        <li data-list-item-id="ecd22464dfb70f395e7ea3b2886c66fff">
                            Don’t Use in patient in HDV positive recipients.
                        </li>
                    </ul>
                    <p>
                        2. Anti-HBc positive +
                    </p>
                    <ul>
                        <li data-list-item-id="e0974405c4d758da07240e251659ddcfa">
                            Use in recipients with HBsAg + recipients (will need HBV anti-viral). &nbsp;
                        </li>
                        <li data-list-item-id="e537d003498362f847210a0cd8f4fc054">
                            Use in recipients with HBsAb + and &nbsp;HBcAb + if previously consented (will not need HBV anti-viral). &nbsp;
                        </li>
                        <li data-list-item-id="e35050c2aec530c24ab63d945dbe4121e">
                            Use in recipients with HBsAb - and &nbsp;HBcAb + if previously consented (will need HBV anti-viral).
                        </li>
                        <li data-list-item-id="ebc0b2effcdbd7bf23a57e8ccb80a7e07">
                            Use in HBV naïve recipients if previously consented (will need HBV anti-viral).&nbsp;
                        </li>
                    </ul>
                </td>
            </tr>
            <tr>
                <td>
                    HCV &nbsp;
                </td>
                <td>
                    Can Use HCV + donors in all patients if they agree and its documents before-hand. &nbsp;
                </td>
            </tr>
            <tr>
                <td>
                    Infections &nbsp;
                </td>
                <td>
                    <p>
                        <strong>Contraindicated</strong>: HIV+, active bacteremia/fungemia, active TB, WNV+, HTLV+ &nbsp;
                    </p>
                    <p>
                        <strong>Acceptable with precautions</strong>: Syphilis+ (treat recipient), CMV+, EBV+, toxoplasma+ &nbsp;
                    </p>
                </td>
            </tr>
            <tr>
                <td>
                    Malignancy &nbsp;
                </td>
                <td>
                    <p>
                        Patients with basal cell carcinoma or squamous cell skin cancer or a CNS cancer (other than medulloblastoma with no VP shunt) OR papillary thyroid cancer &lt; 2 cm then Use. &nbsp;
                    </p>
                    <p>
                        Don’t Use All other cancers. &nbsp;
                    </p>
                </td>
            </tr>
            <tr>
                <td>
                    Liver disease &nbsp;
                </td>
                <td>
                    <p>
                        Any known cirrhosis then Don’t Use &nbsp;
                    </p>
                    <p>
                        If LFTs are elevated (less than 3-time ULL) with no known liver disease and its thought to be related to shocked liver then Use.
                    </p>
                    <p>
                        If LFTs are elevated ( 3-5 time ULL) with no known liver disease and its thought to be related to shocked liver then Use if only one other donor factor abnormal.
                    </p>
                    <p>
                        If LFTS are elevated ( more than 5 times ULL) then don’t Use.&nbsp;
                    </p>
                </td>
            </tr>
            <tr>
                <td>
                    Na level &nbsp;
                </td>
                <td>
                    <p>
                        If Na is &lt;160 then Use.
                    </p>
                    <p>
                        If Na is &gt;160 then &nbsp;Use if only one other donor factor abnormal. &nbsp;
                    </p>
                </td>
            </tr>
            <tr>
                <td>
                    Size match on imaging &nbsp;&nbsp;
                </td>
                <td>
                    Surgeon need to review the images. &nbsp;
                </td>
            </tr>
            <tr>
                <td>
                    Cold ischemic time &nbsp;
                </td>
                <td>
                    <p>
                        &lt;12 hours then Use.
                    </p>
                    <p>
                        12-14 hours then Use if not DCD donor. &nbsp;
                    </p>
                    <p>
                        &gt;14 hours then don’t Use.&nbsp;
                    </p>
                </td>
            </tr>
            <tr>
                <td>
                    Organox
                </td>
                <td>
                    Consider Organox for DCD livers or marginal livers.&nbsp;
                </td>
            </tr>
        </tbody>
    </table>